3.4.17.23 8-[[2-(dimethylamino)ethyl]amino]-5-(hydroxymethyl)-9-oxo-9H-xanthen-2-yl 4-methylbenzenesulfonate enhances ACE2 activity in a dose-dependent manner and causes considerable reductions in blood pressure and a striking reversal of cardiac and renal fibrosis in the spontaneously hypertensive rat model of hypertension 692586 3.4.17.23 all-trans retinoic acid - 679704 3.4.17.23 D-glucose incubation of cells in high D-glucose increases ACE2 activity 732775 3.4.17.23 losartan a specific angiotensin II receptor antagonist, is a well-known antihypertensive drug with a potential role in positively regulating ACE2 in the lung 710616 3.4.17.23 losartan an angiotensin II type 1 receptor blocker, increases central ACE2 activity. Losartan also restores brain ACE2 activity in transgenic RA mice, overview 708683 3.4.17.23 additional information ACE2 activity in plasma is not altered by ibuprofen treatment 764930 3.4.17.23 additional information ACE2 activity is not regulated by ibuprofen, flurbiprofen, etoricoxib or paracetamol 764930 3.4.17.23 additional information no activation by PD123319, an angiotensin II type 2 antagonist 708683 3.4.17.23 resorcinolnaphthalein enhances ACE2 activity in a dose-dependent manner 692586 3.4.17.23 SARS-CoV-2 ACE2 cleavage of des-Arg9-bradykinin substrate analogue is markedly accelerated by SARS-CoV-2 infection, while cleavage of angiotensin II analogue is minimally affected by the binding of spike protein 763217 3.4.17.23 XNT activates ACE2, reduces platelet attachment to injured vessels, reduces thrombus size, and prolonges the time for complete vessel occlusion in mice. Thrombus area is reduced by 60%, whereas time for thrombus formation is prolonged by 45% in XNT-treated mice 709990 3.4.17.23 XNT treatment at 10 mg/kg resultes in a 30% attenuation of thrombus formation in the SHR 709990